Tuesday, May 17, 2011
CytRx Sells Assets To Orphazyme
Los Angeles-based biopharmaceuticals firm CytRx said late last night that it has sold off the firm's molecular chaperone assets, to Denmark-based Orphazyme ApS. The deal is worth as much as $120M, if all development and commercialization milestones are met. The deal also included an up-front payment, which was not disclosed. Orphazyme ApS is venture backed by Novo A/S and Sunstone Capital. CytRx said the move is part of its move to monetize non-core assets at the firm. The firm has been focusing in on its oncology portfolio.
Get More SocalTech Data
Try our two week free trial to find new tech customers, find high tech startups and jobs, find venture funding, and more!Learn More